近日，国际投行高盛发布首份覆盖复宏汉霖（02696.HK）的研究报告，明确给予该股“买入” 评级，设定12个月目标价100.70港元。以该股周四收盘价 66.10 港元计算，这一估值意味着高达52.3%的潜在上行空间。截至10月31日收盘，复宏汉霖股价上涨5.67%，报收69.85港元/股。高盛认为，复宏汉霖正在从生物类似药领域的早期先行者，战略性地转型为全球创新型生物制药公司，而其下一代IO-...
Source Link近日，国际投行高盛发布首份覆盖复宏汉霖（02696.HK）的研究报告，明确给予该股“买入” 评级，设定12个月目标价100.70港元。以该股周四收盘价 66.10 港元计算，这一估值意味着高达52.3%的潜在上行空间。截至10月31日收盘，复宏汉霖股价上涨5.67%，报收69.85港元/股。高盛认为，复宏汉霖正在从生物类似药领域的早期先行者，战略性地转型为全球创新型生物制药公司，而其下一代IO-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.